PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2023/43 - BSC / Ativos B. Braun
Acquired
Assets Aesculap AG
Description
They are part of medical devices indicated for the treatment of anastomotic leaks and perforations in the esophagus or lower pelvic area that give rise to abscess cavities surrounded by necrotic tissue.
Acquired
Assets B. Braun Surgical S.A.
Description
They are part of medical devices indicated for the treatment of anastomotic leaks and perforations in the esophagus or lower pelvic area that give rise to abscess cavities surrounded by necrotic tissue.
Acquiring
Boston Scientific Corporation
Description
Active in Portugal in the development, manufacture and sale of medical devices for interventional medical specialties, including interventional cardiology, endovascular intervention, electrophysiology, endoscopy, radiology/oncology, urology, pulmonary endoscopy and neuromodulation.
Sector
Activity (NACE)
Applicable legislation
Notification thresholds
Type of merger
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description

This merger operation consists of the acquisition by Boston Scientific Corporation (“BCS”) of exclusive control over a set of endoluminal vacuum therapy assets, held by B. Braun Surgical, S.A. and its subsidiary Aesculap AG (“B. Braun”).
Timeline
2023-11-15
The AdC issued a non-opposition decision to the merger 43/2023 - BSC / Ativos B. Braun.
2023-10-04
BSC notifies the acquisition of exclusive control over a set of assets held by B. Braun.
Click here to see your activities